Kymera advances KT-621 and KT-579 ahead of key clinical readouts

Transcript intelligence

What changed

Relative to the prior quarter, the update added first-in-human KT-579 evidence showing more than 90% IRF5 degradation in blood and skin tissue, advanced the program toward a Phase Ib lupus study, and kept KT-621 on track for a year-end Phase IIb readout. Partner programs also progressed, while management said no additional collaboration revenue is anticipated.

Guidance delta

Management guidance sentiment remained maintained. The company expects KT-621 Phase IIb data by year-end, plans Phase III atopic dermatitis development by mid-2027, and expects to fund operations through 2029; no additional collaboration revenue is anticipated.

Key takeaways

• KT-621 Phase IIb atopic dermatitis data are expected by year-end, with Phase III planned for mid-2027.
• KT-579 showed more than 90% IRF5 degradation in blood and skin tissue, with a Phase Ib lupus study planned for early next year.
• Management highlighted a cash runway through 2029 and continued progress in Sanofi and Gilead partner programs.
• The opportunity for oral degraders is meaningful, but efficacy, safety, placebo response, competition, and execution remain unresolved.

Management priorities

• Advance KT-621 toward its Phase IIb readout and planned Phase III atopic dermatitis program.
• Move KT-579 into a Phase Ib lupus study and continue the Phase III asthma program.
• Progress partner programs KT-485 with Sanofi and KT-200 with Gilead, including IND planning for KT-200 in 2027.